Aarti Drugs growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+7.5%−5.6%−6.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.7%−9.3%+3.6%
+4.7%−12.7%+3.8%
+16.0%−2.0%+3.1%
+16.4%−1.1%+3.3%
+9.3%+5.9%+0.5%
+13.1%+6.8%+7.5%
+3.7%−31.9%+167.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAARTIPHARMADVENZYMESAGARWALEYEAKUMSAPLLTDCORONAHCGMcap ₹4,098 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-6.9-5.6+7.5—
EBITDA Growth—+3.6-9.3+7.7—
EBIT Growth—+3.8-12.7+4.7—
Net Income Growth—+3.1-2.0+16.0—
EPS Growth—+3.3-1.1+16.4—
Total Assets Growth—+0.5+5.9+9.3—
Total Equity Growth—+7.5+6.8+13.1—
Cash from Operations Growth—+167.5-31.9+3.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.